Clinical Trial Update: Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic [Phase 2]

View source ↗

Summary

A randomized Phase II trial assessed letrozole with or without dasatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Femara (letrozole) (letrozole)
• Sprycel (dasatinib) (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-05-11